（原标题：首届肿瘤全程管理专题会议在汕头开幕，权威专家共探防治新策略） 2025年11月21日至23日，首届肿瘤全程管理专题会议在广东汕头成功举办。本次会议由广东省药学会、汕头市抗癌协会主办，广东省药学会肿瘤 全程管理专家委员会、汕头大学医学院附属肿瘤医院承办，在国家卫生健康委员会医疗管理服务指导中心及科学技术研究所的支持和指导下，通 过2个主会场、6个高水平平行分论坛，汇聚千余名国内肿瘤领域顶尖专家与骨干力量。 图：第一届肿瘤全程管理专题会议主会场 国家卫健委医管中心副主任陈虎、国家卫健委科学技术研究所所长邢若齐、广东省工业和信息化厅党组成员陈绩、汕头市政府副市长李钊、汕头 大学党委书记唐锐、广州国家实验室主任助理兼办公室主任汪会盛、汕头市卫健局局长杨芳、汕头大学医学院院长夏欧东、汕头大学医学院附属 肿瘤医院党委书记刘思伟、汕头大学医学院附属肿瘤医院院长李杰、武汉大学原副校长唐其柱、南方财经全媒体集团21世纪经济报道总裁虞伟等 领导嘉宾出席及线上参与活动。 作为首届聚焦肿瘤全程管理的区域性学术盛会，本次会议的举办具有重要里程碑意义。它不仅为粤东地区乃至全国肿瘤防治领域搭建了理念碰 撞、技术交流的桥梁，更推动 ...

Core Insights - A strategic cooperation agreement was signed between the China Anti-Cancer Association and JD Health during the China Conference on Integrated Oncology, aiming to enhance cancer prevention and treatment through digital technology and academic resource integration [1][2] Group 1: Collaboration Focus Areas - The partnership will focus on three main areas: cancer prevention and education, physician empowerment, and industry-academia-research collaboration [1][2] - JD Health will integrate the CACA cancer guidelines into its AI medical tools, providing authoritative prevention and treatment concepts to users and patients [1] - A series of public education initiatives will be launched, including live broadcasts on cancer awareness and the release of a "Cancer Prevention Expert List" to encourage expert participation [1] Group 2: Physician Empowerment - JD Health will leverage the academic resources of the China Anti-Cancer Association to organize oncology academic conferences and include CACA guidelines in its oncology academic section [2] - A "Cancer Expert List" will be jointly published to support physician branding, and AI-assisted tools will be developed to enhance service efficiency and patient education [2] Group 3: Industry-Academia-Research Collaboration - JD Health will assist in promoting the research outcomes of association experts in cancer rehabilitation and facilitate technology transfer [2] - Joint research projects will be proposed based on JD's AI capabilities, and both parties will participate in the evaluation of research outcomes to foster innovation in cancer diagnosis and rehabilitation technologies [2] Group 4: Strategic Significance - This collaboration marks the first partnership between JD Health and the China Anti-Cancer Association, combining JD's extensive online cancer patient base and advanced AI algorithms with the association's academic authority and vast network of healthcare professionals [2] - The partnership aims to transition cancer prevention and treatment from "point solutions" to "integrated processes," creating a more efficient and collaborative cancer prevention ecosystem [2]

Core Insights - The field of cancer treatment is undergoing significant transformation driven by advancements in medical technology and a patient-centered approach [1] Group 1: Standardization and Quality of Care - There is a critical issue of "insufficient total resources and uneven distribution" in China's cancer medical resources, necessitating the need for high-quality treatment resources to be more accessible [2] - The core direction for promoting standardized and homogenized treatment is to expand and balance the distribution of quality medical resources [2] - Pharmaceutical companies play a vital role in this process by collaborating with experts to create educational content and help more doctors, especially those in grassroots settings, understand and apply clinical guidelines [2] Group 2: Patient-Centric Management - Recent innovations in targeted and immunotherapy have shifted cancer management from a "disease-centered" to a "health-centered" approach, emphasizing the importance of improving patients' quality of life alongside treatment efficacy [3] - A multi-faceted support system is essential for helping patients cope with emotional challenges and treatment side effects, including family support, accurate disease understanding, and shared experiences from patient organizations [3][4] - Companies are actively involved in developing disease management guidelines from the perspectives of patients and caregivers, which aids in shared decision-making and improves treatment adherence [4] Group 3: Collaborative Decision-Making - The core of comprehensive cancer management lies in breaking the traditional "doctor-led, patient-passive" model and establishing a collaborative decision-making ecosystem [5] - Effective communication between doctors and patients is crucial, as many patients misinterpret professional literature due to a lack of accessible educational materials [5] - Pharmaceutical companies are addressing information gaps by transforming scientific papers into understandable content, facilitating better communication and understanding between patients and healthcare providers [5]

Core Insights - Peng Ruili Group and Nanjing Ruizhong Biotechnology have signed a cooperation agreement to invest 150 million yuan in building a secondary general hospital focused on oncology in Chengdu [1][2] - The new hospital will cover over 25,000 square meters and have approximately 250 beds, aiming to provide comprehensive services for cancer prevention, diagnosis, treatment, and rehabilitation [1][2] - The project is expected to begin trial operations by the end of this year, integrating advanced cancer treatment technologies and expert resources from across the country [1][2] Investment and Development - The new hospital will focus on comprehensive cancer treatment and will explore innovative anti-cancer therapies in collaboration with Nanjing Ruizhong Biotechnology [2] - It will adopt a multidisciplinary team (MDT) approach to create personalized treatment plans for various malignant tumors, including thyroid cancer, lung cancer, liver cancer, pancreatic cancer, prostate cancer, and glioma [2] - The hospital will implement a full-cycle management model, utilizing high-precision imaging and AI-assisted diagnostic systems for early detection and treatment [2] Strategic Positioning - Chengdu Peng Ruili International Medical Health Center is the first "shared medical + high-speed rail hub" complex developed by Singapore's Peng Ruili Group in China, aiming to establish a "highland for innovative cancer treatment" [3] - The hospital will vertically integrate with other institutions within the center to enhance early cancer screening and treatment capabilities, leveraging advanced technologies such as PET-CT and AI imaging analysis [3] - The strategic location near Chengdu East Station will enable comprehensive coverage of the southwestern region, providing hope for more cancer patients through access to cutting-edge technologies [3]